2 completed, 1 terminated, 1 unknown. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Terminated 1 |
Follow ALZA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of S-CKD602 in Patients With Advanced Malignancies S CKD602 - Cancer | Phase 1 | Completed | University of Pittsburgh | 45 | 2003-09-01 | 2013-12-19 |
| Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome amifostine trihydrate, cytarabine, topotecan hydrochloride - Leukemia, Myelodysplastic Syndromes | Phase 2 | Unknown | ALZA | 25 | 1999-01-01 | 2013-12-04 |
| Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer amifostine trihydrate, irinotecan hydrochloride - Colorectal Cancer | Phase 1 / Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 23 | 1997-07-01 | 2020-08-03 |
| CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy CAELYX, Paclitaxel HCl - Ovarian Neoplasms | Phase 3 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 220 | 1997-05-01 | 2010-04-27 |
Anemia, Refractory, with Excess of Blasts (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Leukemia (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Rectal Neoplasms (1)
Amifostine (2) · Cytarabine (1) · Irinotecan (1) · Topotecan (1) · liposomal doxorubicin (1)
United States (3)
Diane Prager, MD (1) · Henry C. Fung, MD, FRCPE (1) · Ramesh K Ramanathan, MD (1)